responses to new compounds. This enables pharmaceutical companies to optimize their clinical trials through large-scale simulations of drug efficacy using internal data (prior to patient enrollment), enrichment strategies to select likely responders, and drug repurposing opportunities. Pharma companies partnering with QuantaBrain can save up to $116M per approved drug.